Enanta Pharmaceuticals, Inc. (ENTA)

NASDAQ: ENTA · USD

$11.6

-0.61 (-5.0%)· Recorded snapshot

Market cap	337M
Revenue (ttm)	65.3M
Net income (ttm)	-63.2M
EPS (ttm)	-$2.34
Shares out	29.1M
Volume	235,431
Beta	0.96

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 65.3M
Net income (ttm): -63.2M
EPS (ttm): -$2.34
Market cap: 337M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-70.1

P25 n/aP50 n/aP75 n/a

ROIC-50.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ENTA indicators

Market & fundamental data

Available fields

212

Groups with data

Currency

USD

Showing 212 of 212 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001177648
Company name	Enanta Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	29251M106
Earnings date	2026-11-16
Earnings time	amc
Employees	120
Employees change	-11
Employees growth	-8.4%
Enterprise value	$307.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	September
Founded	1995
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2013-03-21
Is primary listing	Yes
Is SPAC	No
ISIN number	US29251M1062
Last 10-K release date	2025-11-19
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$337M
Market cap category	Small-Cap
Next earnings date	2026-11-16
Options	Yes
Price	$11.57
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ENTA
U.S. state	Massachusetts
Website	https://www.enanta.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-20.19%
EV/Sales	4.78x
FCF / EV yield	-11.85%
FCF yield	-10.83%
Forward EV/Sales	5.03x
Forward P/S	5.5x
P/B ratio	3.51x
P/S ratio	5.23x
Price / tangible book value	3.38x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-89.99%
EBITDA margin	-82.47%
Gross margin	100%
Operating margin	-89.99%
Pretax margin	-96.74%
Profit margin	-96.89%
Profit per employee	$-526,917
Revenue per employee	$543,817
ROA	-12.28%
ROA (5Y)	-17.73%
ROCE	-24.2%
ROE	-70.12%
ROE (5Y)	-50.76%
ROIC	-50.4%
ROIC (5Y)	-116.1%
SBC / revenue	23.41%
Tax / revenue	0.15%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	7
EPS growth years	2
Gross profit growth	0.7%
Gross profit growth (Q)	-21.6%
Gross profit growth 3Y	-6.79%
Gross profit growth 5Y	-7.65%
Net income growth years	2
Revenue growth	0.7%
Revenue growth (Q)	-21.6%
Revenue growth (QoQ)	-16.32%
Revenue growth 10Y	-3.15%
Revenue growth 3Y	-6.79%
Revenue growth 5Y	-7.65%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.6M
Depreciation and amortization	$4.9M
EBIT	$-58.7M
EBITDA	$-53.8M
EPS	$-2.34
FCF per share	$-1.27
Financing cash flow	$43M
Free cash flow	$-36.9M
Free cash flow minus SBC	$-52.2M
Gross profit	$65.3M
Income taxes	$99,000
Investing cash flow	$-19.1M
Net cash flow	$-11.4M
Net income	$-63.2M
Operating cash flow minus SBC	$-50.6M
Operating income	$-58.7M
Revenue	$65.3M
Stock-based compensation	$15.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-0.94
Book value per share	$3.47
Debt / equity	1.8
Interest coverage	-4.55
Long-term assets	$93.3M
Long-term liabilities	$141.6M
Net cash (debt)	$29.5M
Net cash / market cap	8.63%
Net debt / equity	-0.29
Piotroski F-Score	3
Property, plant and equipment	$67.8M
Shareholders' equity	$101.1M
Tangible book value	$101.1M
Tangible book value per share	$3.47
Total assets	$296.9M
Total cash	$189.5M
Total debt	$182M
Total liabilities	$195.8M
WACC	8.17%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.22
Current assets	$203.6M
Current liabilities	$54.2M
Current ratio	3.76
Net working capital	$637,000
Quick ratio	3.62
Working capital	$149.5M
Working capital turnover	0.4

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-27.12%
Dividend yield	0%
Shareholder yield	-27.12%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-52.17%
10Y return CAGR	-7.11%
10Y total return	-52.17%
150-day SMA	$13.14
1D price change	-5.01%
1M price change	-1.85%
1M total return	-1.85%
1W price change	-0.09%
1W total return	-0.09%
1Y price change	11.05%
1Y return CAGR	11.06%
1Y total return	11.05%
20-day SMA	$11.93
200-day SMA	$13.22
3M price change	-8.41%
3M total return	-8.41%
3Y price change	39.64%
3Y return CAGR	11.77%
3Y total return	39.64%
50-day SMA	$12.63
50-day SMA vs 200-day SMA	50under200
52-week high	$17.15
52-week high date	2025-12-29
52-week low	$10.22
52-week low date	2025-11-07
5Y price change	-85.43%
5Y return CAGR	-31.97%
5Y total return	-85.43%
6M price change	-12.2%
6M total return	-12.2%
All-time high	$127.77
All-time high date	2018-07-06
All-time low	$4.09
All-time low date	2025-04-09
Average true range (ATR)	$0.65
Average volume	257.6K
Beta (1Y)	1.46
Beta (2Y)	1.6
Beta (5Y)	0.96
Change from 52-week high	-32.54%
Change from 52-week low	13.21%
Change from all-time high	-90.87%
Change from all-time low	185.09%
Change from open	0.87%
Day's gap	-5.83%
Dollar volume	$2.7M
High price	$11.72
Low price	$11.10
Monthly RSI	45.41
Open price	$11.47
Position in 52-week range	75.81%
Premarket change	-1.97%
Premarket close	$12.18
Premarket price	$11.94
Premarket volume	1.2K
Previous close	$12.18
Price vs 150-day SMA	-11.28%
Price vs 20-day SMA	-2.26%
Price vs 200-day SMA	-11.81%
Price vs 50-day SMA	-7.68%
Relative volume	0.91
RSI	45.33
Sharpe ratio	0.38
Sharpe ratio (3Y)	0.41
Sharpe ratio (5Y)	-0.22
Sortino ratio	0.66
Sortino ratio (3Y)	0.88
Sortino ratio (5Y)	-0.28
Volume	235.4K
Weekly RSI	44.37
YTD price change	-26.06%
YTD total return	-26.06%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	22.5M
Float percentage	77.32%
Shares change (QoQ)	0.17%
Shares change (YoY)	27.12%
Shares held by insiders	4.54%
Shares held by institutions	76.13%
Shares outstanding	29.1M
Short % of float	11.34%
Short % of shares	8.77%
Short ratio	9.6 days

Deeper analysis on ENTA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ENTA report

Is a complete ENTA research report available?

No complete published report is available for Enanta Pharmaceuticals, Inc. (ENTA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Enanta Pharmaceuticals, Inc. (ENTA)

Price

Financial snapshot

Fair-value bridge

Latest news · ENTA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ENTA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ENTA

Frequently asked questions